Authors:
WIKSTROM P
STATTIN P
FRANCKLISSBRANT I
DAMBER JE
BERGH A
Citation: P. Wikstrom et al., TRANSFORMING-GROWTH-FACTOR BETA-1 IS ASSOCIATED WITH ANGIOGENESIS, METASTASIS, AND POOR CLINICAL OUTCOME IN PROSTATE-CANCER, The Prostate, 37(1), 1998, pp. 19-29
Citation: P. Stattin et al., SHORT-TERM CELLULAR EFFECTS INDUCED BY CASTRATION THERAPY IN RELATIONTO CLINICAL OUTCOME IN PROSTATE-CANCER, British Journal of Cancer, 77(4), 1998, pp. 670-675
Authors:
STATTIN P
BERGH A
KARLBERG L
TAVELIN B
DAMBER JE
Citation: P. Stattin et al., LONG-TERM OUTCOME OF CONSERVATIVE THERAPY IN MEN PRESENTING WITH VOIDING SYMPTOMS AND PROSTATE-CANCER, European urology, 32(4), 1997, pp. 404-409
Citation: If. Lissbrant et al., VASCULAR DENSITY IS A PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PROSTATIC-CARCINOMA, The Prostate, 33(1), 1997, pp. 38-45
Citation: P. Stattin et al., CELL-PROLIFERATION ASSESSED BY KI-67 IMMUNOREACTIVITY ON FORMALIN-FIXED TISSUES IS A PREDICTIVE FACTOR FOR SURVIVAL IN PROSTATE-CANCER, The Journal of urology, 157(1), 1997, pp. 219-222
Citation: P. Stattin et al., PRETREATMENT P53 IMMUNOREACTIVITY DOES NOT INFER RADIORESISTANCE IN PROSTATE-CANCER PATIENTS, International journal of radiation oncology, biology, physics, 35(5), 1996, pp. 885-889
Authors:
STATTIN P
BERGH A
KARLBERG L
NORDGREN H
DAMBER JE
Citation: P. Stattin et al., P53 IMMUNOREACTIVITY AS PROGNOSTIC MARKET FOR CANCER-SPECIFIC SURVIVAL IN PROSTATE-CANCER, European urology, 30(1), 1996, pp. 65-72
Authors:
STATTIN P
DAMBER JE
KARLBERG L
NORDGREN H
BERGH A
Citation: P. Stattin et al., BCL-2 IMMUNOREACTIVITY IN PROSTATE TUMORIGENESIS IN RELATION TO PROSTATIC INTRAEPITHELIAL NEOPLASIA, GRADE, HORMONAL STATUS, METASTATIC GROWTH AND SURVIVAL, Urological research, 24(5), 1996, pp. 257-264
Citation: P. Stattin et al., LONG-TERM OUTCOME OF PATIENTS TREATED FOR HYDROCELE WITH THE SCLEROSANT AGENT SODIUM TETRADECYL SULFATE, Scandinavian journal of urology and nephrology, 30(2), 1996, pp. 109-113
Citation: P. Westin et al., CASTRATION THERAPY RAPIDLY INDUCES APOPTOSIS IN A MINORITY AND DECREASES CELL-PROLIFERATION IN A MAJORITY OF HUMAN PROSTATIC TUMORS, The American journal of pathology, 146(6), 1995, pp. 1368-1375